Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 3 July 2013
Revision date: 17-May-2019
Length: 27 pages
Data source: Field research
Topics:
Long term financing; Disruptive innovation; Financing; Foreign investments; Capital-asset-pricing; Agile software development; Value propositions; Philanthropies; Venture capital; Mergers & acquisitions (M&A); Politics; Co-branding; Strategic philanthropy; Collaborative innovation; Net profit
Abstract
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to the integration of Aurora into Vertex were still unresolved, the most pressing being Aurora's major collaboration with the Cystic Fibrosis Foundation (CFF). Were venture philanthropy and foundation deals an appropriate funding mechanism for a public company like Vertex? How could the board of Vertex and the CFF fundamentally align the objectives of a for-profit company with those of a non-profit institution? Those were the questions faced by the Vertex executives.
Location:
Industries:
About
Abstract
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to the integration of Aurora into Vertex were still unresolved, the most pressing being Aurora's major collaboration with the Cystic Fibrosis Foundation (CFF). Were venture philanthropy and foundation deals an appropriate funding mechanism for a public company like Vertex? How could the board of Vertex and the CFF fundamentally align the objectives of a for-profit company with those of a non-profit institution? Those were the questions faced by the Vertex executives.
Settings
Location:
Industries: